ES2097120T3 - Estabilizacion de proteinas altamente purificadas. - Google Patents

Estabilizacion de proteinas altamente purificadas.

Info

Publication number
ES2097120T3
ES2097120T3 ES90113210T ES90113210T ES2097120T3 ES 2097120 T3 ES2097120 T3 ES 2097120T3 ES 90113210 T ES90113210 T ES 90113210T ES 90113210 T ES90113210 T ES 90113210T ES 2097120 T3 ES2097120 T3 ES 2097120T3
Authority
ES
Spain
Prior art keywords
protein
stabilization
highly purified
purified proteins
carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90113210T
Other languages
English (en)
Inventor
Michael H Coan
Vivian W Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23517903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of ES2097120T3 publication Critical patent/ES2097120T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN CARBOHIDRATO, TAL COMO MANITOL O DEXTRAN-70 SE AÑADE DURANTE LA PURIFICACION DE UNA PROTEINA, TAL COMO EL FACTOR VIII:C. EL CARBOHIDRATO ESTABILIZA LA PROTEINA, INCLUSO CUANDO LA PROTEINA SE ENCUENTRA ENTRE EL 60 Y 99% DE PUEREZA. EL CARBOHIDRATO SE AÑADE A TRAVES DE VARIOS PASOS DE PURIFICACION Y ESTA PRESENTE EN EL ENVASE FINAL PARA, DE ESTA FORMA, ESTABILIZAR LA PROTEINA DURANTE SU CONGELACION EN SECO Y SU RECONSTITUCION.
ES90113210T 1989-07-24 1990-07-11 Estabilizacion de proteinas altamente purificadas. Expired - Lifetime ES2097120T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38458489A 1989-07-24 1989-07-24

Publications (1)

Publication Number Publication Date
ES2097120T3 true ES2097120T3 (es) 1997-04-01

Family

ID=23517903

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90113210T Expired - Lifetime ES2097120T3 (es) 1989-07-24 1990-07-11 Estabilizacion de proteinas altamente purificadas.

Country Status (8)

Country Link
EP (1) EP0410207B1 (es)
JP (1) JPH0358998A (es)
AT (1) ATE148165T1 (es)
CA (1) CA2021452A1 (es)
DE (1) DE69029765T2 (es)
DK (1) DK0410207T3 (es)
ES (1) ES2097120T3 (es)
GR (1) GR3022614T3 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US6165467A (en) * 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
EP1336107B1 (en) 1999-07-14 2009-01-07 Spectral Diagnostics Inc. Preparation of spheres for diagnostic tests
AU3070702A (en) 2000-11-07 2002-05-21 Chiron Corp Stabilized inteferon compositions
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
DK1417301T3 (da) * 2001-08-07 2007-03-12 Novozymes As Carbonhydrater og polyoler til oplösning af proteinkrystaller
KR20030060660A (ko) * 2002-01-10 2003-07-16 손정일 앞/뒷면 구별 없는 양면 양말
CA2492143A1 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
JP2008501639A (ja) * 2004-04-23 2008-01-24 ノベシン リミテッド タンパク質を安定化、保護及び可溶化させるための方法及びキット
EP1749018B1 (en) * 2004-04-23 2014-10-22 Expedeon Limited Methods and kits for stabilising, protecting and solubilising proteins
CN101605532A (zh) * 2007-02-16 2009-12-16 惠氏公司 含有山梨糖醇的蛋白质调配物
US8183233B2 (en) 2008-05-15 2012-05-22 Baxter International Inc. Stable pharmaceutical formulations
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
JP6029651B2 (ja) * 2011-04-29 2016-11-24 オンコリティクス バイオテク，インコーポレーテッド ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法
US10238718B2 (en) 2014-08-04 2019-03-26 Csl Limited Factor VIII formulation
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media

Also Published As

Publication number Publication date
DE69029765T2 (de) 1997-05-15
ATE148165T1 (de) 1997-02-15
GR3022614T3 (en) 1997-05-31
JPH0358998A (ja) 1991-03-14
EP0410207A2 (en) 1991-01-30
EP0410207B1 (en) 1997-01-22
EP0410207A3 (en) 1992-01-15
CA2021452A1 (en) 1991-01-25
DE69029765D1 (de) 1997-03-06
DK0410207T3 (da) 1997-07-14

Similar Documents

Publication Publication Date Title
ES2097120T3 (es) Estabilizacion de proteinas altamente purificadas.
DE3874798D1 (de) Therapeutisches proteinagens in form von aerosol.
CA2085750A1 (en) Osteoinductive pharmaceutical formulations
DE68928956D1 (de) Verfahren zur Herstellung von optisch aktivem 1,3-Butanediol
DE69230670D1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
DK0409472T3 (da) Knoglemorfogenetisk protein
DE59308628D1 (de) Verfahren zur Herstellung von Faktor VIII
ATE95564T1 (de) Aeusseres membranprotein f von pseudomonas aeruginosa.
DE69219622D1 (de) Herstellung von optisch aktiven aliphatischen carbonsäuren
ATE73462T1 (de) Hirudin-variante, deren verwendung und herstellung.
CA2105282A1 (en) Preparation of factor ix
ES2058479T3 (es) Compuestos peptidicos.
DE69313099D1 (de) Herstellung von optisch aktiven aliphatischen carbonsäuren
ES2104686T3 (es) Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia.
NO942323D0 (no) Soyaprotein eller hydrolysater i farmasöytiske preparater for beskyttelse av bioaktive peptider mot enzymatisk inaktivering
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
ATE101607T1 (de) Aroylharnstoffe.
DE69534738D1 (de) Leukocyten-aktivierender Faktor
DE3888543D1 (de) Zusammensetzungen zur herstellung von gasdurchlässigen kontaktlinsen.
DE59305709D1 (de) Verfahren zur Herstellung von 1,4-Diaminoanthrachinon-2,3-disulfonsäure und 1,4-Diaminoanthrachinon-2,3-dinitril
DE68915694D1 (de) Verfahren zur Herstellung von verzweigten 1,3-Glykolen und ihren Monoestern.
DK0741746T3 (da) Thymosin alpha 1-analoger
DE59307374D1 (de) Verfahren zur Herstellung von 5-Halogen-2-(1-anthrachinonylamino)benzoesäuren und 4'-Halogen-2,1(N)-anthrachinonyl-1',2'(N)-benzacridonen
ATE96153T1 (de) Gereinigtes protein mit angiogenischer wirkung und dessen herstellung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 410207

Country of ref document: ES